title: [pT3R1 prostate cancer : Immediate or delayed radiotherapy after radical prostatectomy?].
abstract: Approximately 50-60% of patients with tumor stage pT3R1 after radical prostatectomy (RP) who do not receive adjuvant therapy develop biochemical progression. At present it is unclear whether these patients should undergo immediate adjuvant irradiation or whether a wait and see approach should be adopted while monitoring PSA until the PSA level rises from zero and then initiate salvage radiotherapy (SRT).Three randomized trials showed that an absolute improvement of 20% in the 5-year biochemical no evidence of disease (bNED) could be achieved by administering adjuvant radiotherapy with 60 Gy in patients with tumor stage pT3R1, even with a PSA level around zero after RP. The rate of serious late effects is low. On the other hand, there are numerous, albeit retrospective studies, which provide evidence that SRT after an increase in PSA above zero is an effective treatment, but with higher total doses of 66-70 Gy and a higher rate of late effects. Prognostic factors such as the PSA level before radiotherapy is started, PSA doubling time, R1 resection, PSA velocity, and the Gleason score have a significant impact on both the return of the PSA level to zero and the bNED. Depending on the risk factor, between 20 and 70% of patients again achieve PSA levels around zero after SRT. Retrospective comparative studies suggest a benefit of adjuvant radiotherapy; prospective randomized trials do not exist.Adjuvant radiotherapy after RP in stage pT3R1 tumor and SRT in cases of PSA rising above zero or persistent PSA levels are valid options for the management of high-risk patients after RP. SRT requires higher total doses and thus carries a higher risk of late complications. A benefit has been demonstrated for bNED, but not for survival. The approach should be discussed with the individual patient.
authors.affiliation: Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm, Robert-Koch-Strasse 6, 89081, Ulm, Deutschland. dirk.bottke@uniklinik-ulm.de
authors.forename: D
authors.initials: D
authors.lastname: Bottke
authors.forename: T
authors.initials: T
authors.lastname: Wiegel
mesh_terms: D014408:Biomarkers, Tumor / Q000097:blood; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy* / Q000601:surgery*; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D016879:Salvage Therapy
chemical_list: D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen